{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:44:16Z","timestamp":1770749056061,"version":"3.50.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and whilst advances have been made in the pathophysiology, diagnostics and management of other podocytopathies, primary FSGS remains the most elusive. It has been assumed for a long time that a circulatory permeability factor exists that mediates podocyte injury, and the potential for autoantibody-mediated disease therefore raises the question as to whether patients may benefit from targeted B-cell therapy with rituximab. The prospective case series of seven patients by Roccatello et\u00a0al. adds to the limited but growing evidence suggesting that B-cell depletion therapy can be safe and effective in the treatment of primary FSGS. In this editorial we explore the available evidence that suggests how and in whom rituximab may play a role in the management of primary FSGS, as well as the limitations and other potential future treatments. Further research and randomized controlled trials are needed to include larger numbers of patients, feature genetic screening and incorporate data on B-cell kinetics as a potential guide for dosing and frequency of rituximab.<\/jats:p>","DOI":"10.1093\/ckj\/sfad122","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T06:06:43Z","timestamp":1684994803000},"page":"1199-1205","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice?"],"prefix":"10.1093","volume":"16","author":[{"given":"Adam D","family":"Morris","sequence":"first","affiliation":[{"name":"Department of Nephrology, Lancashire Teaching Hospitals NHS Foundation Trust , Preston , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Floyd","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Lancashire Teaching Hospitals NHS Foundation Trust , Preston , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3825-6955","authenticated-orcid":false,"given":"Alexander","family":"Woywodt","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Lancashire Teaching Hospitals NHS Foundation Trust , Preston , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Dhaygude","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Lancashire Teaching Hospitals NHS Foundation Trust , Preston , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"2023073100364332300_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4132\/jptm.2016.09.21","article-title":"Pathogenesis of focal segmental glomerulosclerosis","volume":"50","author":"Lim","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"2023073100364332300_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2023073100364332300_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib4","first-page":"1","article-title":"Focal segmental glomerular sclerosis can be effectively treated using an intensive B cell depletion therapy","volume":"0","author":"Roccatello","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023073100364332300_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1056\/NEJM200102013440517","article-title":"Transmission of glomerular permeability factor from a mother to her child","volume":"344","author":"Kemper","year":"2001","journal-title":"N Engl J Med"},{"key":"2023073100364332300_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100364332300_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1681\/ASN.V103552","article-title":"The FSGS factor:\u201d enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma","volume":"10","author":"Sharma","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2013.544","article-title":"A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease","volume":"85","author":"Wada","year":"2014","journal-title":"Kidney Int"},{"key":"2023073100364332300_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1681\/ASN.2022010070","article-title":"A novel mouse model of idiopathic nephrotic syndrome induced by immunization with the podocyte protein Crb2","volume":"33","author":"Hada","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med"},{"key":"2023073100364332300_bib11","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"2023073100364332300_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-12-81","article-title":"Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"key":"2023073100364332300_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00467-014-2892-6","article-title":"Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children","volume":"30","author":"Peng","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2023073100364332300_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ki.2014.346","article-title":"A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease","volume":"87","author":"Spinale","year":"2015","journal-title":"Kidney Int"},{"key":"2023073100364332300_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2013.546","article-title":"Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"2023073100364332300_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3396","article-title":"Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome","volume":"20","author":"Clement","year":"2014","journal-title":"Nat Med"},{"key":"2023073100364332300_bib17","doi-asserted-by":"crossref","first-page":"e0176198","DOI":"10.1371\/journal.pone.0176198","article-title":"Angiopoietin-like-4 and minimal change disease","volume":"12","author":"Cara-Fuentes","year":"2017","journal-title":"PLoS One"},{"key":"2023073100364332300_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1681\/ASN.2007111244","article-title":"Induction of T regulatory cells attenuates idiopathic nephrotic syndrome","volume":"20","author":"Le Berre","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib20","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00467-010-1507-0","article-title":"Characterisation of renal immune cell infiltrates in children with nephrotic syndrome","volume":"25","author":"Benz","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"2023073100364332300_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"2023073100364332300_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/scitranslmed.3008538","article-title":"A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation","volume":"6","author":"Delville","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023073100364332300_bib23","doi-asserted-by":"crossref","first-page":"714964","DOI":"10.1155\/2015\/714964","article-title":"Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family","volume":"2015","author":"Savin","year":"2015","journal-title":"J Immunol Res"},{"key":"2023073100364332300_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2023073100364332300_bib25","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2215\/CJN.01190216","article-title":"Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis","volume":"11","author":"Zhang","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100364332300_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s10157-018-1585-z","article-title":"Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria","volume":"22","author":"Huang","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2023073100364332300_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000346256","article-title":"Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial","volume":"37","author":"Ren","year":"2013","journal-title":"Am J Nephrol"},{"key":"2023073100364332300_bib28","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"2023073100364332300_bib29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2215\/CJN.11941115","article-title":"T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS","volume":"11","author":"Chan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100364332300_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ekir.2021.10.017","article-title":"Efficacy of rituximab in treatment-resistant focal segmental glomerulosclerosis with elevated soluble urokinase-type plasminogen activator receptor and activation of podocyte \u03b23 integrin","volume":"7","author":"Hladunewich","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023073100364332300_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477944","article-title":"High-dose rituximab ineffective for focal segmental glomerulosclerosis: a long-term observation study","volume":"46","author":"Roccatello","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023073100364332300_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00508-013-0366-7","article-title":"Rituximab in adult patients with multi-relapsing\/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases","volume":"125","author":"Kronbichler","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"2023073100364332300_bib33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2169\/internalmedicine.51.6854","article-title":"Rituximab treatment for adult patients with focal segmental glomerulosclerosis","volume":"51","author":"Ochi","year":"2012","journal-title":"Intern Med"},{"key":"2023073100364332300_bib34","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.ekir.2022.05.024","article-title":"The role of rituximab in primary focal segmental glomerular sclerosis of the adult","volume":"7","author":"Tedesco","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023073100364332300_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1372859","article-title":"Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome","volume":"2017","author":"Stahl","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"2023073100364332300_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2023073100364332300_bib37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100364332300_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2023073100364332300_bib39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"Apol1 nephropathy: from genetics to clinical applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023073100364332300_bib40","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/ndt\/gfr771","article-title":"Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice","volume":"27","author":"Rood","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2023073100364332300_bib41","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.xkme.2022.100501","article-title":"Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"4","author":"Caster","year":"2022","journal-title":"Kidney Med"},{"key":"2023073100364332300_bib42","first-page":"CD003233","article-title":"Interventions for focal segmental glomerulosclerosis in adults","volume":"2022","author":"Hodson","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2023073100364332300_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.xkme.2021.01.013","article-title":"Health-related quality of life in focal segmental glomerular sclerosis and minimal change disease: a qualitative study of children and adults to inform patient-reported outcomes","volume":"3","author":"Carlozzi","year":"2021","journal-title":"Kidney Med"},{"key":"2023073100364332300_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"2023073100364332300_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","article-title":"Rituximab for refractory focal segmental glomerulosclerosis","volume":"23","author":"Nakayama","year":"2008","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad122\/50539239\/sfad122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1199\/50925908\/sfad122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/8\/1199\/50925908\/sfad122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:37:11Z","timestamp":1690763831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/8\/1199\/7179420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,5,24]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad122","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,5,24]]}}}